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Abstract 
Solubility can be the absorption limiting factor for drug candidates and is therefore a very important input 
parameter for oral exposure prediction of compounds with limited solubility. Biorelevant media of the 
fasted and fed state have been published for humans, as well as for dogs in the fasted state. In a drug 
discovery environment, rodents are the most common animal model to assess the oral exposure of drug 
candidates. In this study a rat simulated intestinal fluid (rSIF) is proposed as a more physiologically relevant 
media to describe drug solubility in rats. Equilibrium solubility in this medium was tested as input 
parameter for physiologically-based pharmacokinetics (PBPK) simulations of oral pharmacokinetics in the 
rat. Simulations were compared to those obtained using other solubility values as input parameters, like 
buffer at pH 6.8, human simulated intestinal fluid and a comprehensive dissolution assay based on rSIF. Our 
study on nine different compounds demonstrates that the incorporation of rSIF equilibrium solubility values 
into PBPK models of oral drug exposure can significantly improve the reliability of simulations in rats for 
doses up to 300 mg/kg compared to other media. The comprehensive dissolution assay may help to 
improve further simulation outcome, but the greater experimental effort as compared to equilibrium 
solubility may limit its use in a drug discovery environment. Overall, PBPK simulations based on solubility in 
the proposed rSIF medium can improve prioritizing compounds in drug discovery as well as planning dose 
escalation studies, e.g. during toxicological investigations. 
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Introduction 
The use of physiologically-based pharmacokinetic (PBPK) modeling in drug development has matured 
and aims at prediction of plasma-concentration time profiles based on both in silico and in vitro 
parameters. Regardless of the advancement of the modeling software itself, the success of PBPK 
approaches to support decision making will strongly depend on the use of appropriate input parameters. 
This is particularly true in drug discovery, when the robustness of input parameters is naturally lower 
compared to data generated in later stage development.  
A recent overview on the use of PBPK models for oral dosage forms is given by Kostewicz et al. [1]. 
Many reports about its use and years of application at various stages of drug development have generated 
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two main strategies for implementation of PBPK in early drug discovery.  
On the one hand simulation approaches can be compared to observed data as a strategy to build 
hypothesis regarding differences and sensitivity of input parameters. To prove or disprove such a 
hypothesis, results may be used to initiate further studies in order to identify the underlying reason for 
discrepancies between simulated and observed results. Another strategy is to use PBPK approaches to 
perform pharmacokinetic prediction across species, contributing to increased confidence in the design of 
preclinical toxicology studies and ultimately reliable prediction of human pharmacokinetics.  
In order for PBPK approaches to have impact in a drug discovery setting we need to be confident of 
performance reliability. The quality of PBPK simulations during this early phase is often compromised by 
the lack of validated input data. There is greater confidence with human PBPK prediction based on the fact 
that at this stage of drug development, a broad set of robust input data is available. In addition, many 
aspects of human physiology have been studied in much greater detail compared to preclinical species. 
Although rodents, especially rats, are still the most relevant screening model in drug discovery, many 
parameters relevant for drug ADME properties are not known in detail or show a high variability. Even 
within one defined rat strain, a broad range of values is typically reported in the literature [2,3].  
It is clear that solubility can play a major role in the drug absorption process, particularly when dealing 
with poorly soluble compounds. As the majority of compounds in current research pipelines of 
pharmaceutical industry are classified into the BCS class II category [4], i.e. drug absorption is limited by 
solubility, it is very important to assess the development risk of such drug candidates at a very early stage 
of the process when choices among different chemical structures are still possible.  
In order to provide PBPK simulation software with better solubility input parameters, the use of 
solubility values in human FaSSIF (fasted-state simulated intestinal fluid) has been proposed before. Many 
publications refer to human PK prediction [5], but FaSSIF has been proposed as input parameters for rats, 
too [6]. As rats are lacking a gall bladder, their GI tract is exposed to a constant bile flow at concentrations 
higher than in any other typical preclinical species. Reported bile salt concentrations in rats are in the range 
of 12-51 mM [7-9].  
Human bio-relevant fluids are undoubtedly relevant dissolution media in order to assess the 
performance of drug candidates in a clinical research and development environment. However, the 
decision to move a potential drug candidate forward is taken during the pre-clinical phase. Up to the point 
of compound selection for clinical development, these compounds have only been tested in typical pre-
clinical species, like rats, dogs, monkeys or minipigs. The role of solubility in the gastrointestinal tract of a 
particular species becomes evident, as soon as a compound of low solubility has shown reasonable PK 
parameters in rodents and is selected for testing of PK properties in a non-rodent species. Potentially, 
solubility may be one of the main factors that limit human bioavailability prediction based on animal 
studies [10], in case solubility in human GI fluids is significantly lower than in GI fluids of preclinical species. 
Solubilization of compounds in the GI fluids is mainly driven by bile salt and phospholipid contents. To 
what extent differences in fluid composition influence solubility across species has been demonstrated in a 
comparison of solubility of drug molecules in human and dog GI fluids [11]. For this reason, the impact of 
solubility on PBPK simulation results has been widely studied, especially the use of high-throughput vs. 
thermodynamic equilibrium solubility data. Gao et al. [6] have described a way to generate solubility input 
parameters for PBPK simulations of rats by applying a full GI dissolution profile that takes into 
consideration the constant dilution by fluid secretion along the GI transit, as well as formulation options 
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that could lead to differences in supersaturation and re-precipitation behavior. However, their model is 
based on human FaSSIF to mimic the dilution in the rat GI fluid. Due to the sensitivity of solubility to bile 
salts, which is expected for many compounds in drug discovery, solubility tested in the proposed simulated 
rat fluid should improve the prediction power of PBPK simulations when rodents are the species of 
interest. 
In this publication, we describe a way to generate a simulated rat intestinal fluid (rSIF) and study its 
impact on PBPK simulation for rats. The results are compared to simulations which use other solubility 
input values, like solubility in buffer pH 6.8, FaSSIF and the dissolution curve generated by an in vitro GI 
dissolution assay [6]. In addition, bile salt dependent solubility estimated based on log P is included in this 
comparison [12].  
Materials and Methods 
Physico-chemical measurements 
Passive permeability of the compounds was investigated using the PAMPA assay [13]. In the current 
work, the log PAMPA value has been used, which represents the highest value of effective permeability 
from three measured values at pH 4, pH 6.8 and pH 8.   
Equilibrium solubility was determined using the shake-flask method using about 1.5 mg of compound. 
The mixture was shaken for 20 to 24 hours and the solid phase was separated by centrifugation for 15 min 
at 2000g. Concentration of the compound in the supernatant was determined by HPLC-UV (Agilent 1200) 
based on an external calibration curve.  
The partition coefficient log P was determined for ionizable compounds by potentiometric titration 
(Sirius T3, Sirius Instruments Ltd.). Non-ionizable compounds were analyzed by reverse-phase HPLC.  
Determination of the acid dissociation constant (pKa) was done by potentiometric titration (Sirius T3, 
Sirius Instruments Ltd.).  
Preparation of test media 
Buffer solution from Merck KGaA; pH 6.8; 0.1 M di-sodium hydrogen phosphate / potassium hydrogen 
phosphate was used. 
Preparation of human FaSSIF-V2 was done based on the suggestion by Jantratid et al. [14]. To obtain 
one liter of clear FaSSIF-V2, sodium taurocholate and sodium chloride were first dissolved in 400 ml of 
purified water, followed by the addition of 1 ml of 1 M HCl. After stirring for 30 min, lecithin was added and 
the mixture was sonicated until complete dissolution and stirred for another two hours. Then, maleic acid 
and 500 ml of water were added. After overnight stirring, the pH was adjusted to 6.5 by addition of 1M 
NaOH and the total volume was adjusted to 1 L.  
Simulated rat intestinal fluid 
A rat simulating intestinal fluid (rSIF) was developed as surrogate to mimic intestinal conditions in vivo 
with regard to bile salt and phospholipid concentrations, surface tension, pH, buffer capacity and 
osmolarity [15]. This was done to supplement previously published human [14] and canine [11] media. Due 
to unavailability of sufficient ex vivo samples, published information was used to define the target 
properties of rSIF. Table 1 compares the main properties of rSIF with human FaSSIF-V2. 
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Table 1. Main properties of rat simulated intestinal fluid (rSIF) in comparison to human FaSSIF-V2 
 rSIF FaSSIF-V2 
pH 6.0 6.5 
Buffer capacity [mmol/l/pH] 15.2 10 
Surface Tension [mN/m] 42 54.3 
Osmolality [mOsmol/kg] 480 180 
Bile Salt Concentration [mM] 25 3 
Phospholipid Concentration [mM] 5.16 0.2 
 
Due to the constant bile flow in rats due to a lack of a gall bladder and most typical housing conditions 
with constant access to food, a homostatic condition was assumed for rats. In consequence, fasted and fed 
states were not distinguished for the rat medium. 
Rat intestinal pH was averaged to 6.0 based on values reported elsewhere [2,16,17]. An average was 
selected to reflect the main areas of absorption within the proximal intestine with reported pH values 
between 5.0 and 7.1. To allow higher throughput, use of multiple pH media was neglected. 
Adjustment of surface tension had to be balanced with bile salt and phospholipid concentrations. 
Addition of cholic acid and chenodeoxycholic acid sodium was required to achieve targeted surface tension 
values. It was found that combination of bile salts provided a synergistic effect and provided best reduction 
of surface tension.  Both substances are reported to be present in rat bile fluids and thus have physiological 
relevance [18]. Surface tension values obtained for rSIF are in line with recent data [19]. Bile salt and 
phospholipid concentrations are slightly above values referenced and used for example in GastroPlus 
models and other references [17]. The values for buffer capacity were estimated taking into account 
human FaSSIF-V2 and the constant bile flow, as there was no reference available at the time of rSIF 
development. Recent data from Merchant [19] indicate that this value appears to be too low.  
Depending on new insights rSIF may be further refined with regard to bile salt concentration, buffer 
capacity and osmolality. Further refinement of media could also reflect more section specific pH and bile 
concentrations in analogy to human media published [14].  
 
Table 2. Composition of rSIF; 100 ml target volume  
 Conc. (mM) Molecular weight (g/mol) Weighted sample (mg) 
Sodium taurocholate 5.00 537.7 269 
NaCl 18.70 58.0 108 
Lecithin 5.16 775.0 400 
Maleic acid 29.86 116.1 347 
Purified water - - q.s. 
NaOH 1 N - - q.s. 
Sodium oleate 0.26 304.4 8 
Sodium cholate hydrate 12.50 430.6 538 
Sodium 
chenodeoxycholic acid 
7.50 414.6 311 
Glyceryl Monooleate 1.67 356.5 60 
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Preparation of rSIF           
In order to prepare 100 ml of rSIF, a composition according to Table 2 was used. Sodium taurocholate, 
sodium cholate hydrate, sodium chenodeoxycholic acid and NaCl were dissolved in 50 ml of purified water. 
After stirring for 30 min, lecithin, sodium oleate and glyceryl monooleate were added. Subsequently, the 
mixture was sonicated for about 5-10 min and stirred overnight. A clear solution was obtained. Maleic acid 
and 40 ml of purified water were added, resulting in a suspension of pH around 2.2. The pH was adjusted 
to 6.0 by 1 M NaOH. The mixture was stirred until a clear solution was obtained. If needed, the pH was 
adjusted, again. Finally, the volume was filled up to 100 ml by addition of purified water.  
The surface tension was determined in triplicates using a Kibron delta-8 tensiometer (Kibron Inc., 
Helsinki). An average value of 42.8 mN/m was obtained.  
PBPK simulations 
PBPK simulations were performed using the ACAT model of the GastroPlus software (Simulations Plus 
Inc., Lancaster) version 8.6.  
The distribution and elimination were described by a compartmental PK model. The number of 
compartments and parameters of the model were obtained by fitting the in vivo i.v. time-concentration 
profiles in the PKPlus module of Gastroplus. 
The absorption was predicted by the ACAT model in Gastroplus using the “rat physiological fasted” GI 
tract and based on the physico-chemical and in vitro ADME properties of the compounds.   
The permeability of the compound was characterized by measurement in PAMPA. First, a calibration of 
the PAMPA assay to the Gastroplus permeability Peff input parameter was carried out. It was based on the 
curve of PAMPA versus human fraction absorbed for 83 marketed compounds. The curve of the Gastroplus 
intrinsic permeability Peff versus human fraction absorbed was obtained by varying the Peff value, see Figure 
1. The correlation between PAMPA and Peff was obtained by matching the two curves.  
To be consistent with other data of internal databases an animal weight of 250 g was used. This is 
slightly below the actual weight of animals in the current study. The difference in simulation outcome has 
been tested for selected cases (data not shown) and is rather small. No effect on the ranking of the 
simulation results has been observed. The animals had free access to food, thus the feeding state was 
uncontrolled, neither fasted nor fed. Due to the lack of the gall bladder, the difference between fasted and 
fed state for rats is regarded as to be small. As tested (data not shown), the impact of physiology of the 
simulation model is marginal in comparison to the solubility impact. Thus, the fasted rat physiology was 
used.  
The Absorption Scaling Factor model, designed to take into account the regional changes in 
permeability, was the “Opt logD Model SA/V 6.1”. The scaling coefficient C4 in the colon was set to zero in 
order to avoid overestimation of colonic absorption as outlined in equation (1):  
 
C DASF C 4log3 10   (1) 
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Figure 1: Peff conversion based on log PAMPA measurements 
As a consequence, the original model led to high absorption for all lipophilic drugs regardless of their 
PAMPA (or Caco-2) permeability, which did not match our observations. The property space of the training 
set used in the GastroPlus software where poorly permeable compounds are typically hydrophilic 
molecules does not match the property space of our discovery molecules that are characterized by a 
higher average molecular weight and for which poor permeability is not exclusively driven by low 
lipophilicity. 
The liver first-pass extraction was estimated with the well-stirred model based on in vitro microsomal 
clearance without taking into account plasma protein binding or microsomal binding. This approach was 
found to be reasonable by Parrot et al [12], Germani et al [21] and Jones et al [22]. It was compared with 
the estimation based on the in vivo clearance and provided better predictions (see Figure 2).  
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a) Liver first pass based on in vivo clearance 
 
b) Liver first pass based on microsomal clearance 
Figure 2: Comparison of the performance of the model between the estimation of the liver first pass with the 
in vivo clearance (a) and microsomal clearance (b) for 61 proprietary compounds administered to rats. 
The octanol-water partition coefficient log P is based on measured values. For all suspensions, a particle 
radius of 7 m was assumed, which is a typical number based on our experience with compounds in the 
lead optimization phase. Typically, the unknown solid state and the impact of the amorphous form are 
supposed to play a major role for particle dissolution, which may overrule the particle size effect.  
Information about dose dependence of systemic clearance is typically not available in the lead 
optimization stage and the assumption made in this study is that clearance does not significantly change 
with the dose. 
Pharmacokinetic studies 
Pharmacokinetic studies have been performed in male Sprague-Dawley rats, originating from Charles 
River Wiga (Germany). The experiment was performed according to the regulations effective in the Canton 
Basel-City, Switzerland. 
Six to four days before first drug administration, the rats (body weight approx. 270-330 g) were 
anesthetized and catheters were surgically implanted into the femoral artery (for blood collection) and 
femoral vein (for intravenous injection). The catheters were exteriorized at the neck where they were fixed 
via the tether and a flexible spring to a Harvard swivel system, which allowed blood sampling and 
intravenous injections without disturbing the freely-moving animal. For analgesic treatment, animals 
received Temgesic (10 µg kg-1 s.c.) before surgery and subsequently twice at appropriate times after 
surgery. Animals were kept individually in Macrolon cages, with free access to food and water throughout 
the experiment. 
Dosing i.v. and p.o. was performed in two different animal groups. For per oral administration, the 
compounds were formulated as a suspension in methyl cellulose. For intravenous administration, the 
compounds were dissolved in an appropriate mixture of N-methyl pyrrolidone (NMP) and poly(ethylene 
glycol) 200 (PEG). For sample analysis, approximately 50 µl of blood was taken. 30 µL of blood was mixed 
with 200 µL of acetonitrile and centrifuged at 4 °C.  Approx. 200 µL of supernatant was transferred into a 
microtiter plate and mixed with 200 µL 0.1 % formic acid. An aliquot of each sample was injected into the 
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LC-MS/MS system for analysis. 
GI dissolution assay 
Full GI dissolution was performed by a modified setup based on the proposal of Gao et al. [6]. Their GI 
dissolution model takes into consideration the transit times in the stomach and four additional segments in 
the intestine. Gao et al. included the dilution that is supposed to happen during the transit through the 
gastrointestinal tract. In particular, dilution was based on basal acid output, the pancreatic juice secretion 
rate and the bile flow. Gao et al. proposed a basal acid output of 0.8657 ml/4 h/100 g. In order to calculate 
the dilution in the small intestine, a pancreatic juice secretion rate of 0.033 ml/min/kg is suggested; bile 
flow is set to 70 ml/day/kg in their setup. The corresponding transit times are 0.25 h in the stomach and 
0.2, 2.0, 4.5 and 8 h for duodenum, jejunum/ileum, cecum and colon, respectively. Dilution in the stomach 
is supposed to be caused by basal acid output only. In the small intestine, the basal acid output adds to the 
secretion of pancreatic juice and bile. Based on these assumptions, dilution factors of 1.5 for the stomach, 
1.9 for the duodenum, 5.8 for jejunum/ileum and 2.9 for the cecum were proposed. No further dilution 
was considered in the colon, since most fluid had been absorbed.  
For improved differentiation of weakly basic compounds in our setup, the pH of the stomach 
compartment was lowered to pH 3. As dilution medium the rSIF as proposed in Table 2 was used instead of 
FaSSIF-V2. 
Results and Discussion 
In vitro solubility studies 
In order to study the difference of equilibrium solubility in the proposed rat fluid (rSIF) in comparison to 
buffer solubility and human FaSSIF-V2, a set of proprietary compounds has been investigated by the shake-
flask method. The compounds have been selected based on availability of in vivo data, and sufficient 
compound amount for running solubility and GI dissolution studies. Also, only compounds exhibiting high 
in vitro permeability have been chosen, thus keeping the impact of permeability on drug absorption low.  
Solubility results in buffer pH 6.8, human FaSSIF-V2 and rSIF media for the selected compounds are 
summarized in Table 3.  
 
Table 3. Solubility (g/L) of selected compounds in buffer pH 6.8, FaSSIF-V2 in comparison to rSIF 
 buffer pH 6.8 FaSSIF-V2 rSIF 
Compound A 0.001 0.0041 0.105 
Compound B 0.004 0.0001 0.448 
Compound C 0.031 0.043 0.711 
Compound D 0.005 0.003 0.023 
Compound E <0.0005 0.0009 0.046 
Compound F 0.05 0.14 0.881 
Compound G 0.003 0.013 0.193 
Compound H 0.0002 0.0005 0.01 
Compound I 0.0025 0.002 0.015 
Mostly compounds exhibiting low solubility in both buffer pH 6.8 and FaSSIF-V2 have been selected. 
Solubility in rSIF can differ vastly from the other two media investigated, thus leading to the assumption 
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that FaSSIF-V2 solubility is not able to provide a realistic input parameter for PBPK simulations in the rat. 
Compound F has been selected as an example of acceptable solubility in FaSSIF-V2, but rSIF still showing a 
7-fold higher equilibrium value. This result will be used as a test case whether solubility in rSIF would lead 
to over-prediction in PBPK simulations. 
Bile salt dependent solubility  
There is little doubt that the use of thermodynamic solubility values in buffers in many cases will not be 
very useful to predict in vivo concentration-time profiles. With the exception of well soluble compounds 
with good wetting properties, buffer solubility values will most likely underestimate the in vivo 
solubilization of most molecules. Since the introduction of the human FaSSIF and FeSSIF media, there is an 
option to obtain solubility values which are more appropriate as input parameters for PBPK simulations 
and FaSSIF solubility maybe one of the physico-chemical parameters that is determined as one of the first 
after a compound is sent out for characterization.  
However, to properly assess the risk for clinical development it is necessary to understand the impact of 
solubility on in vivo absorption during lead optimization and thus in preclinical species. Although the FaSSIF 
and FeSSIF media allow studying the potential solubility limitation for absorption in humans, they may not 
be appropriate input parameters in preclinical species. The bile salt concentration in gastrointestinal fluids 
in the fasted dog is known to be at the level of human FeSSIF rather than FaSSIF [11], and the situation in 
rats is substantially different. Due to the absence of a gall bladder and thus a constant bile flow, factors 
limiting absorption in a rat may be rather different as compared to the situation in humans. As bile salt 
concentrations in rat GI fluids are reported up to a level of 51 mM [9] the rat is likely to be a better 
solubilizer for lipophilic compounds which might be better absorbed than in higher species.   
The GastroPlus software includes an estimation of bile salt dependent solubility based on log P 







  (2) 
 
where SCbs is defined as the solubilization capacity of bile salt (moles drug/mole bile salt) and SCaq is 
defined as the solubilization capacity of water (moles drug/mole water).  
For their set of compounds, they found: 
 
SR Plog 2.23 0.61log   (3) 
 
This approach was evaluated based on a dataset of proprietary compounds. For these compounds, 
buffer solubility and the solubility in buffer containing various amount of sodium taurocholate was 
determined, see Table 4. To calculate SCbs, the molar solubility at a defined bile salt concentration was 
divided by the actual bile salt concentration, i.e. 10, 50 or 100 mM in our data set. SCaq, correspondingly, is 
obtained by dividing the molar solubility in buffer pH 6.8 by 55.5 mol/liter.  
Calculation of the log P dependence of the solubility ratio (SR) as defined by Mithani et al. led to a linear 
regression similarly to the equation as proposed by Mithani, see Figure 3. While this data principally 
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supports the linear dependency of SR on log P, this equation is based on a fit through several orders of 
magnitude for both log P and log SR, which will compromise the ability to predict individual solubility 
values with the accuracy required for PBPK modeling. In order to estimate the predictive power of the 
Mithani equation, the calculated values and the measured solubility at different bile salt concentrations are 
displayed in Figure 3. For some of the compounds of the test set (see Table 4) the variation in SR can be 
more than one order of magnitude within the different concentration of bile salts used to determine the 
solubility, i.e. 10, 50 or 100 mM. The maximum difference to the linear fit is found to be about 2 log units 
of SR. Importantly, the differences to the linear fit do not appear to be markedly log P dependent. Also, the 
increase in solubility with increasing bile salt concentration for many compounds is not a linear 
dependency, see Table 4.  
Table 4. Solubility test set for taurocholate concentrations of 10, 50 and 100 mM. S indicates solubility in buffer at pH 
6.8. Calculated solubility ratio according to taurocholate concentrations (log SR10, log SR50, log SR100), based on the 
Mithani equation (1). 
 Mw Log P 
pKa 
acid/base 







Cpd 1 529.5 5.2 5.4b; 3.9b 0.0019 17.78 483.2 666.9 7.718 8.453 8.292 
Cpd 2 379.4 3.2 3.4b 0.022 0.04 0.26 0.34 4.004 4.118 3.933 
Cpd 3 560.5 4.1 8.2b; 3.7b 0.0054 0.42 3.95 5.49 5.639 5.913 5.755 
Cpd 4 558.2 4.6 9.1b; 4.1b 0.001 0.7 4.12 4.07 6.589 6.660 6.354 
Cpd 5 577.8 4.9 9.1b; 3.9b 0.3202 10.8 11.02 11.23 5.272 4.582 4.289 
Cpd 6 410.4 2.6 5.1b 0.0975 2.27 4.35 9.86 5.111 4.695 4.749 
Cpd 7 485.5 4.3 4.2b 0.001 <0.001 0.15 0.34 - 4.907 4.962 
Cpd 8 453.6 3.1 3.7b 0.0066 0.01 0.01 0.01 3.924 3.225 2.924 
Cpd 9 710.7 7.1 5.11a; 3.8b 0.0014 0.03 1.27 1.9 5.073 6.001 5.875 
Cpd 10 313.4 3.7 n.d. 0.16 0.14 1.6 - 3.686 4.045 - 
Cpd 11 361.3 3.9 11.7a 0.14 0.46 0.51 0.63 4.261 3.607 3.398 
 






















Figure 3. log P dependence of solubility ratio at 10 mM (log SR10), 50 mM (log SR50) and 100 mM (logSR 100) 
taurocholate concentration. The linear fit is based on log SR100, the crosses represent the prediction 
according to equation (2). 
As a consequence, due to the significant deviations from the linear fit for many compounds, the 
estimation of bile salt solubility for individual compounds is regarded as not sufficient to support studying 
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the impact of solubility in PBPK simulations. The estimation of log P dependent solubilization ratio might be 
justified in cases where no bile salt dependent solubility can be determined, however, there remains a risk 
of being misled. This is especially true for low soluble compounds, as changes of solubility by only a factor 2 
to 4 might strongly impact the absorption profile of a compound. Thus, FaSSIF solubility will not provide 
accurate enough information to further extrapolate the contribution of bile salt solubilization at 
concentrations that are assumed to mimic the in vivo situation in rats.  
PBPK Simulations 
The importance of solubility input parameters for PBPK simulations of low soluble compounds is 
indisputable. At low dose, a significant portion of a compound administered might be dissolved in the 
stomach and subsequently be absorbed. However, at a higher dose, there is a larger portion remaining 
undissolved. Thus, the solubilization power of the intestinal fluid is more relevant for the absorption of 
higher doses. As a consequence, GI dissolution profiles adapted to the relevant species should positively 
impact the prediction results, especially for Cmax. To test this hypothesis, GastroPlus simulations have 
been performed at different dose levels and simulation results are compared to in vivo results.  
Compounds with no expected permeability limitation according to in vitro data (PAMPA) and low to 
moderate total blood clearance have been selected to investigate the impact of solubility parameters on 
PBPK simulations, see Table 5. A systematic approach was chosen to compare the impact of solubility on 
the simulation results for the selected compounds. Five different solubility input parameters have been 
chosen. First, the thermodynamic equilibrium solubility in buffer was used, without correction for bile salt 
solubilization. In a next step, the FaSSIF solubilty value was used to calculate the solubilization ratio (SR). 
Based on the data in Table 4, the theoretical SR calculation as provided by the GastroPlus software was 
tested in another approach. The rat SIF fluid solubility was used without any correction for bile salt 
content, similar to the thermodynamic solubility value. According to the authors’ experience, correction of 
bile salt dependent solubility using the built-in in vitro SR calculation compromises the value of the 
solubility in the proposed rat SIF medium. Finally, if not limited by compound availability, the full 
dissolution curve was recorded to mimic the dissolution properties of the compound during its transit 
through the rat gastrointestinal tract, based on the modified procedure of Gao et al.[6].  
Table 5. Summary of input parameters for PBPK simulations. First pass extraction ratio (ER%) based on rat liver 
microsomes. Clearance as a result of fit to in vivo data by the PKPlus module. The volume of distribution into the 












Vc, V2, V3 
Compound A 77 3.8 Base -3.9 1.7  0.42 0.38, 0.15, 1.67 
Compound B 28 5.4 Acid -4.0 3.7 1.10 3.28, 4.58 
Compound C 92 <3 base -3.6 3.6 3.48 2.77, 0.95, 1.74 
Compound D 25 4.7 Base -3.6 3.5 0.98 4.32, 3.50, 17.62 
Compound E 56 2.7 Base -3.5 4.2 0.42 0.88, 2.19 
Compound F 67 3.2 Base -3.4 3.1 0.42 0.46, 0.47 
Compound G 55 3.4 Base -4.6 3.9 3.36 4.50, 0.80 
Compound H 38 3.5 Base -4.5 5.3 1.34 3.74, 7.19 
Compound I 37 1.7 Base -4.2 2.8 5.19 2.57, 0.55 
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The PBPK simulation results based on the ACAT model have been split into lower and higher dose 
studies and are summarized in Tables 6 to 9. Simulation results are compared to in vivo data from 
compounds dosed orally as suspension.  
PBPK results 
Lower range of p.o. doses 
The impact of various solubility input parameters on PBPK simulation results has been tested. As 
evaluation criteria for the success of PBPK simulations versus the in vivo PK results, Cmax and AUC were 
chosen, see Table 6 and Table 7. Different solubility input parameters have been tested, as described 
above (see Table 3). In addition, the full GI dissolution profile at the respective dose has been measured 
and the solubility values for each compartment have been entered according to the method section.  
Table 6. PBPK results of Cmax in g/mL for lower dose range based on various solubility input. Cmax buffer, FaSSIF, 
FaSSIF with theoretical bile salt correction (Cmax FaSSIF bile) and rSIF refer to equilibrium values, whereas GI disso 

















Compound A 10 5.041 0.035 0.273 0.089 2.185  
Pred. vs. obs.   0.0069 0.0542 0.0175 0.4333  
Compound B 3 0.138 0.012 0.012 0.040 0.238  
Pred. vs. obs.   0.0869 0.0869 0.2896 1.7246  
Compound C 3 0.134 0.028 0.043 0.046 0.045  
Pred. vs. obs.   0.2089 0.3208 0.3432 0.3358  
Compound D 3 0.213 0.053 0.057 0.124 0.167 0.204 
Pred. vs. obs   0.2488 0.2676 0.5822 0.7840 0.9577 
Compound E 10 2.211 0.069 0.071 0.609 1.502 1.517 
Pred. vs. obs   0.0312 0.0321 0.2754 0.6793 0.6861 
Compound F 10 3.753 2.743 2.743 2.742 2.743 2.308 
Pred. vs. obs   0.7309 0.7309 0.7306 0.7309 0.6150 
Compound G 3 0.020 0.004 0.030 0.022 0.074 0.073 
Pred. vs. obs   0.2000 1.500 1.100 3.700 3.650 
Compound H 3 0.082 0.0007 0.0007 0.031 0.037 0.071 
Pred. vs. obs   0.0085 0.0085 0.3780 0.4512 0.8659 
Compound I 3 0.056 0.011 0.008 0.020 0.062  
Pred. vs. obs   0.1964 0.1429 0.3571 1.107  
 
Results for the lower dose range (see Table 6, Table 7 and Figure 4) support the assumption that the 
buffer solubility typically leads to an underprediction of both Cmax and AUC. The only exception is 
compound F, despite the fact that its solubility in rSIF is much higher than in buffer and FaSSIF-V2 media. 
Apparently, its rather high permeability and sufficient solubility lead to nearly complete absorption, yet if 
the lowest measured solubility value is used. Even a ten times higher solubility value, according to rSIF in 
vitro results, does not change the predicted concentration-time profile for this compound for the 10 mg/kg 
dose.  
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Table 7. PBPK results of AUC (0-t) in g h/mL for lower dose range based on various solubility input. AUC buffer, 
FaSSIF, FaSSIF with theoretical bile salt correction (AUC FaSSIF bile) and rSIF refer to equilibrium values, whereas GI 
disso comprises the input of the full GI dissolution profile. Pred. vs. obs. denotes the ratio of the predicted values vs. 















Compound A 10 16.51 0.186 1.08 0.407 5.05  
Pred. vs. obs   0.0113 0.0654 0.0247 0.3059  
Compound B 3 1.928 0.146 0.146 0.414 1.867  
Pred. vs. obs   0.0757 0.0757 0.2147 0.9684  
Compound C 3 0.232 0.064 0.069 0.070 0.071  
Pred. vs. obs   0.2759 0.2974 0.3017 0.3060  
Compound D 3 2.631 0.570 0.607 1.154 1.570 1.802 
Pred. vs. obs   0.2166 0.2307 0.4386 0.5967 0.6849 
Compound E 10 26.4 0.758 0.795 4.803 9.351 9.335 
Pred. vs. obs   0.0287 0.0301 0.1819 0.3542 0.3536 
Compound F 10 13.4 7.812 7.812 7.823 7.812 7.734 
Pred. vs. obs   0.5830 0.5830 0.5838 0.5830 0.5772 
Compound G 3 0.131 0.020 0.116 0.090 0.285 0.260 
Pred. vs. obs   0.1527 0.8855 0.6870 2.176 1.985 
Compound H 3 1.06 0.007 0.007 0.228 0.312 0.546 
Pred. vs. obs   0.0066 0.0066 0.2151 0.2943 0.5151 
Compound I 3 0.571 0.038 0.033 0.062 0.19  
Pred. vs. obs   0.0665 0.0578 0.1086 0.3327  
 
When the in vitro equilibrium solubility in FaSSIF is used to correct the bile salt dependent solubility, an 
improved prediction is found in a number of cases. In order to allow for an estimate of bile salt dependent 
solubility in case FaSSIF solubility data is not available, the use of the theoretical bile solubilization ratio 
may be an option. As shown in Table 4 the results of this method might significantly deviate from the 
measured values. As the results in Table 6 and Table 7 suggest, for most of the investigated compounds the 
use of the theoretical bile salt ratio leads to an improved prediction, but underprediction for low solubility 
compounds can still be significant.  
When comparing the simulation results that were generated using the in vitro rat SIF solubility, for 
nearly all compounds of the current test set an improved prediction result is achieved. This is reflected in a 
maximum deviation of the predicted value vs the observed value by a factor of at least 3. For some 
compounds even the range of 2-fold variation is reached. Overprediction was observed only in one case 
(compound G), for which even FaSSIF-V2 solubility resulted in a too high value of Cmax.  
In case of compound D and H, the full GI dissolution further improves the simulation outcome. 
However, taking into account the time and effort to record the dissolution profile, it appears justified to 
use rSIF equilibrium solubility instead.  
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AUC buffer AUC FaSSIF AUC FaSSIF bile AUC rat fluid AUC GI disso
Cpd A    Cpd B   Cpd C   Cpd D   Cpd E     Cpd F     Cpd G   Cpd H     Cpd I
 
Figure 4. a) Cmax and b) AUC from simulations performed on studies comprising doses from a 3 to 10 mg/kg 
dose 
 
Observations at higher p.o. doses 
Compared to low p.o. doses, the solubility and dissolution properties of a compound are assumed to 
impact the overall PK profile in an even stronger way when higher doses area applied.  
PBPK results for doses from 30 to 300 mg/kg are summarized in Table 8 and Table 9. Figure 5 displays 
the results as ratio of predicted vs. observed for both Cmax and AUC. Based on rSIF solubility, predicted Cmax 
a) 
b) 
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of all compounds tested is found within a 3-fold range as compared to observed values, most of them even 
within 2-fold. The difference to all other equilibrium solubility values investigated is even more 
pronounced and full GI dissolution does not necessarily help improving the quality of PBPK prediction. The 
example of compound F reveals, again, that there is no influence of solubility for this compound, as already 
pointed out for the lower dose studies. 
Table 8. PBPK results of Cmax in g/mL for higher dose range based on various solubility input. Cmax buffer, FaSSIF, 
FaSSIF with theoretical bile salt correction (Cmax FaSSIF bile) and rSIF refer to equilibrium values, whereas GI disso 


















Compound A 30 8.581 0.047 0.401 0.121 4.139  
Pred. vs. obs   0.0055 0.0467 0.0141 0.4823  
Compound A 100 18.3 0.042 0.468 0.127 4.02  
Pred. vs. obs   0.0023 0.0256 0.0069 0.2197  
Compound B 30 0.784 0.022 0.023 0.119 1.531  
Pred. vs. obs   0.0280 0.0293 0.1518 1.953  
Compound C 30 0.546 0.041 0.101 0.236 0.447 0.491 
Pred. vs. obs   0.0751 0.1850 0.4322 0.8187 0.8993 
Compound D 30 0.908 0.095 0.058 0.271 0.380 2.04 
Pred. vs. obs   0.1046 0.0639 0.2985 0.4185 2.2467 
Compound E 100 3.592 0.094 0.220 1.227 3.869 4.74 
Pred. vs. obs   0.0262 0.0612 0.3416 1.077 1.320 
Compound F 100 17.0 26.3 27.3 25.9 27.4 27.4 
Pred. vs. obs   1.547 1.610 1.524 1.612 1.612 
Compound G 30 0.813 0.005 0.055 0.038 0.274 0.263 
Pred. vs. obs   0.0062 0.0677 0.0467 0.3370 0.3235 
Prediction of AUC in the dose range 30 to 300 mg/kg follows the same trend as for Cmax. rSIF solubility, 
besides the GI dissolution assay, provides best matches of PBPK results without a tendency to overpredict. 
For instance, for compound B at a dose of 3 mg/kg, without using the rSIF solubility but the calculated 
solubilization ratio an under-prediction of AUC by a factor of 5 was found. At the dose of 30 mg/kg, the 
under-prediction was nearly 10-fold, whereas the simulation based on rat SIF fluid led to an excellent 
match for AUC with a factor of 1.3-fold.  
There are still results where AUC is underpredicted by a factor of more than five. One may hypothesize 
that for these cases, the impact of other parameters than solubility, like first pass extraction, might be 
more important in limiting exposure.  
Our results obtained with nine compounds and across different dose ranges show that the rSIF solubility 
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Table 9. PBPK results of AUC (0-t) in g h/mL for higher dose range based on various solubility input. AUC buffer, 
FaSSIF, FaSSIF with theoretical bile salt correction (AUC FaSSIF bile) and rSIF refer to equilibrium values, whereas GI 
disso comprises the input of the full GI dissolution profile. Pred. vs. obs. denotes the ratio of the predicted values vs. 
















Compound A 30 41.3 0.514 2.057 0.861 15.2  
Pred. vs. obs   0.0124 0.0498 0.0209 0.3680  
Compound A 100 97.5 0.297 2.48 0.766 19.2  
Pred. vs. obs   0.0030 0.0254 0.0079 0.1969  
Compound B 30 11.4 0.274 0.274 1.274 14.75  
Pred. vs. obs   0.0240 0.0240 0.1118 1.2939  
Compound C 30 6.99 0.175 0.317 0.521 0.706 0.874 
Pred. vs. obs   0.0250 0.0454 0.0745 0.1010 0.1250 
Compound D 30 14.83 1.139 0.707 2.900 4.27 18.02 
Pred. vs. obs   0.0768 0.0477 0.1955 0.2879 1.215 
Compound E 100 56.9 1.14 4.80 15.1 35.8 44.0 
Pred. vs. obs   0.0200 0.0844 0.2654 0.6292 0.7733 
Compound F 100 268 78.0 78.1 78.2 78.1 78.1 
Pred. vs. obs   0.2910 0.2914 0.2918 0.2914 0.2914 
Compound G 30 6.25 0.033 0.279 0.202 1.249 1.225 
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Figure 5. Observed a) Cmax and b) AUC results from simulations performed on studies comprising doses from a 
30 to 300 mg/kg dose 
Conclusions 
Biorelevant solubility parameters can be markedly different across species. For proper prediction of 
solubility mediated exposure limitation in human, one needs to understand the solubility limitation across 
in vivo species. A good exposure in rats will not necessarily translate into acceptable human drug 
absorption, if solubility is mainly driven by bile salt solubilization, or may lead to an undesired absorption 
profile, like a strong food effect. Even good exposure in a non-rodent species, like dog, might not be 
indicative of the situation in humans, as the dog intestinal fluid still contains bile salts at a level that is close 
to the post-prandial situation in humans. 
a) 
b) 
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A better understanding of the impact of solubility when drug absorption is studied in various species 
helps to lower the risk of failure in clinical studies. For this, a rat simulated intestinal fluid (rSIF) is proposed 
to support understanding the role that solubility plays for absorption of a particular drug candidate. 
The proposed rat SIF greatly improves the quality of PBPK predictions in rats. It explains why some 
compounds that are low soluble in aqueous media nevertheless show good p.o. exposure in rats and why 
this might not always translate to higher species. The results presented in this study allow for a better 
prediction of exposure in rats across the dose range of interest. In addition, a better understanding of 
solubility mediated exposure in rats will help to better anticipate the risk of solubility limited exposure in 
higher species and ultimately in humans.   
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